A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
June 1, 2021
End Date
February 28, 2026
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
June 1, 2021
End Date
February 28, 2026